Bausch + Lomb Co. (NYSE:BLCO) Position Boosted by Alberta Investment Management Corp

Alberta Investment Management Corp lifted its position in Bausch + Lomb Co. (NYSE:BLCO) by 36.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,008,193 shares of the company’s stock after buying an additional 796,400 shares during the quarter. Alberta Investment Management Corp’s holdings in Bausch + Lomb were worth $54,328,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. River Road Asset Management LLC grew its stake in shares of Bausch + Lomb by 4.4% in the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock valued at $38,974,000 after buying an additional 85,987 shares in the last quarter. King Street Capital Management L.P. acquired a new position in shares of Bausch + Lomb during the third quarter worth approximately $14,122,000. Barclays PLC bought a new stake in Bausch + Lomb in the third quarter valued at $5,797,000. Point72 DIFC Ltd bought a new stake in Bausch + Lomb in the third quarter valued at $4,331,000. Finally, Renaissance Capital LLC grew its position in Bausch + Lomb by 116.2% in the fourth quarter. Renaissance Capital LLC now owns 94,182 shares of the company’s stock valued at $1,701,000 after acquiring an additional 50,622 shares during the period. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

NYSE:BLCO opened at $16.40 on Wednesday. The firm has a market capitalization of $5.78 billion, a price-to-earnings ratio of -15.61, a P/E/G ratio of 2.13 and a beta of 0.46. Bausch + Lomb Co. has a 52-week low of $13.16 and a 52-week high of $21.69. The stock has a fifty day moving average of $17.51 and a 200 day moving average of $18.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

Analysts Set New Price Targets

Several analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Bausch + Lomb in a report on Tuesday. Bank of America restated an “underperform” rating and set a $18.00 target price on shares of Bausch + Lomb in a report on Thursday, December 12th. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $22.00 in a research note on Wednesday, December 11th. Stifel Nicolaus dropped their target price on Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a research report on Wednesday, January 29th. Finally, Morgan Stanley downgraded Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus price target of $20.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.